Results 31 to 40 of about 7,374,862 (391)

Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

BMC Cancer, 2017
Background Whether perioperative blood transfusions (PBTs) adversely influence oncological outcomes for intrahepatic cholangiocarcinoma (ICC) patients after curative resection remains undetermined. Methods Of the 605 patients who underwent curative liver
Pei-Yun Zhou, Zheng Tang, Wei-Ren Liu, Meng-Xin Tian, Lei Jin, Xi-Fei Jiang, Han Wang, Chen-Yang Tao, Zhen-Bin Ding, Yuan-Fei Peng, Shuang-Jian Qiu, Zhi Dai, Jian Zhou, Jia Fan, Ying-Hong Shi   +14 more
doaj   +1 more source

SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial–mesenchymal transition and mitochondrial function maintenance

Cancer Medicine, 2023
Background SQSTM1/p62 is a selective autophagy receptor that regulates multiple signaling pathways participating in the initiation and progression of tumors.
Jiafeng Chen, Zheng Gao, Xiaogang Li, Yinghong Shi, Zheng Tang, Weiren Liu, Xin Zhang, Ao Huang, Xuanming Luo, Qiang Gao, Guangyu Ding, Kang Song, Jian Zhou, Jia Fan, Xiutao Fu, Zhenbin Ding   +15 more
doaj   +1 more source

Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH

Hepatology, 2022
Background and Aim: The etiology of liver diseases has changed in recent years, but its impact on the comparative burden of liver cancer between males and females is unclear. We estimated sex differences in the burden of liver cancer across 204 countries
D. Tan, V. Setiawan, C. Ng, W. Lim, M. Muthiah, E. Tan, Y. Dan, L. Roberts, R. Loomba, Daniel Q. Huang   +9 more
semanticscholar   +1 more source

Small Molecule‐Induced Differentiation As a Potential Therapy for Liver Cancer

Advanced Science, 2022
Despite the efficacy demonstrated by immunotherapy recently, liver cancer still remains one of the deadliest cancers, mainly due to heterogeneity of this disease. Continuous exploration of new therapeutics is therefore necessary.
Xu Zhang, Xiang‐Jie Zhu, Zhi Zhong, Jiang‐Chuan Du, Guo‐Xu Fang, Xiu‐liang Cui, Ling‐Ting Guan, Yan‐Yu Hu, Hong‐Yang Wang, Pei‐Lin Zhang   +9 more
doaj   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

Advances in the surgical treatment of liver cancer.

BioScience Trends, 2022
Liver resection is the standard curative treatment for liver cancer. Advances in surgical techniques over the last 30 years, including the preoperative assessment of the future liver remnant, have improved the safety of liver resection.
H. Maki, K. Hasegawa
semanticscholar   +1 more source

Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis

Journal of Translational Medicine, 2020
Background Fibrinogen-like protein 1 (FGL1)—Lymphocyte activating gene 3 (LAG-3) pathway is a promising immunotherapeutic target and has synergistic effect with programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1).
Mengzhou Guo, Feifei Yuan, Feng Qi, Jialei Sun, Qianwen Rao, Zhiying Zhao, Peixin Huang, Tingting Fang, Biwei Yang, Jinglin Xia   +9 more
doaj   +1 more source

KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma

Cancer Cell International, 2022
Background While the correlation between PD-L1 expression and KRAS mutation has been previously reported in other solid tumors such as non-small cell lung cancer (NSCLC), whether PD-L1 can be modulated by ERK signaling downstream of KRAS in intrahepatic ...
Zheng Gao, Jia-Feng Chen, Xiao-Gang Li, Ying-Hong Shi, Zheng Tang, Wei-Ren Liu, Xin Zhang, Ao Huang, Xuan-Ming Luo, Qiang Gao, Guo-Ming Shi, Ai-Wu Ke, Jian Zhou, Jia Fan, Xiu-Tao Fu, Zhen-Bin Ding   +15 more
doaj   +1 more source

High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models. [PDF]

, 2016
Liver metastasis is the main cause of colon cancer-related death and is a recalcitrant disease. We report here the efficacy and safety of intra-portal-vein (iPV) targeting of Salmonella typhimurium A1-R on colon cancer liver metastasis in a nude-mouse ...
Bouvet, Michael, Clary, Bryan M, Hiroshima, Yukihiko, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Murakami, Takashi, Suetsugu, Atsushi, Unno, Michiaki, Zhang, Yong, Zhao, Ming   +11 more
core   +3 more sources

Radiotherapy for liver cancer [PDF]

Journal of General and Family Medicine, 2017
AbstractIn recent years, radiotherapy for liver cancer has accomplished much technical progress. The history of radiotherapy for liver cancer shows an endeavor to overcome the problem of how to raise the irradiation dose to lesions while suppressing the unnecessary irradiation dose to normal liver tissue.
Toshiyuki Okumura, Hideyuki Sakurai, Nobuyoshi Fukumitsu   +2 more
openaire   +2 more sources